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High exposures to bioactivated cyclophosphamide are related to
the occurrence of veno-occlusive disease of the liver following
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We investigated whether the occurrence of veno-occlusive disease of the liver (VOD) may be associated with individual variations in
the pharmacokinetics of high-dose cyclophosphamide. Patients received single or multiple courses of cyclophosphamide (1000 or
1500mgm
 2day
 1), thiotepa (80 or 120mgm
 2day
 1) and carboplatin (265–400mgm
 2day
 1) (CTC) for 4 consecutive days.
The area under the plasma concentration–time curves (AUCs) were calculated for cyclophosphamide and its activated metabolites
4-hydroxycyclophosphamide and phosphoramide mustard based on multiple blood samples. Possible relationships between the
AUCs and the occurrence of VOD were studied. A total of 59 patients (115 courses) were included. Four patients experienced
VOD after a second CTC course. The first-course AUC of 4-hydroxycyclophosphamide (P¼0.003) but not of phosphoramide
mustard (P¼0.101) appeared to be predictive of the occurrence of VOD after multiple courses. High exposures to bioactivated
cyclophosphamide may lead to increased organ toxicity.
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Cyclophosphamide is an alkylating agent widely used in clinical
oncology in both conventional and high-dose chemotherapy
regimens. It has been shown that large interindividual variation
in clinical effect exist with cyclophosphamide treatment and it has
been proposed that these varied responses (both efficacy and
toxicity) may reflect interpatient differences in metabolism and
distribution of the drug (Huitema et al, 2002). However, relation-
ships between the pharmacokinetics of cyclophosphamide and its
biological effects are incompletely understood. This is partly
explained by the complex metabolic profile of cyclophosphamide
(Figure 1) and incomplete understanding of which compounds are
involved in clinical response and toxicity.
Cyclophosphamide itself is an inactive prodrug. Approximately
70–80% of the administered drug is bioactivated by cytochrome
P450 enzymes to form 4-hydroxycyclophosphamide. 4-Hydroxy-
cyclophosphamide is unstable and decomposes into phosphor-
amide mustard, the ultimate alkylating metabolite. In contrast to
4-hydroxycyclophosphamide, phosphoramide mustard cannot
enter target cells, and therefore only the intracellularly formed
phosphoramide mustard fraction is considered to be cytotoxic.
Plasma concentrations of 4-hydroxycyclophosphamide are there-
fore a good marker of the alkylating activity of cyclophosphamide
(De Jonge et al, 2005).
The dose-limiting toxicity of cyclophosphamide at conventional
doses is myelosuppression, primarily leukopenia. In the setting of
bone marrow transplantation, where higher cyclophosphamide
doses can be used, the toxicity profile of cyclophosphamide
includes haemorrhagic cystitis, hepatic damage (veno-occlusive
disease of the liver (VOD)) pulmonary toxicity and cardiac
necrosis (Fraiser et al, 1991). Several authors have reported
weak relationships between exposure or clearance of cyclo-
phosphamide and its efficacy and toxicity (Ayash et al, 1992;
Nieto et al, 1999; Petros et al, 2002; Yule et al, 2004). However, few
studies have focused on relationships between exposure to
cyclophosphamide metabolites and the occurrence of toxicity
or efficacy. An indication for a correlation between high exposures
to 4-hydroxycyclophosphamide or phosphoramide mustard
and the occurrence of VOD was given in three different studies
(Honjo et al, 1988; Ren and Slattery, 1999; Huitema et al,
2002). High exposures to the inactive carboxyphosphamide
have also been related to increased incidence of VOD (McDonald
et al, 2003), which was explained by a positive correlation
between 4-hydroxycyclophosphamide and carboxyphosphamide
formation.
Veno-occlusive disease of the liver is a life-threatening
complication of myeloablative regimens (Shulman et al,
1980; Ayash et al, 1990; Nevill et al, 1991; McDonald et al,
1993, 2003). Therefore, we investigated whether a significant
relationship could be found between exposures to 4-hydroxycy-
clophosphamide and phosphoramide mustard and the occurrence
of VOD.
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Patients and treatment
Patients received the cyclophosphamide, thiotepa and carboplatin
(CTC) high-dose chemotherapy regimen with peripheral blood
progenitor cell transplantation as described previously (Rodenhuis
et al, 1996, 1998, 1999, 2003; Schrama et al, 2001). Patients had
either high-risk primary breast cancer and received high-dose
chemotherapy as part of their adjuvant treatment, or had advanced
breast, germ-cell or ovarian cancer.
Two different high-dose CTC schedules were used. The full-dose
CTC regimen consisted of 4 days of chemotherapy with cyclo-
phosphamide (1500mgm
 2day
 1) as a 1h infusion, immediately
followed by carboplatin (400mgm
 2day
 1) as a daily 1h infusion,
and thiotepa (120mgm
 2day
 1) divided over two 30-min infu-
sions (the second daily dose of TT was administered 12h after the
first dose) (Rodenhuis et al, 1998, 2003). The ‘tiny’ CTC regimen
(tCTC) was identical to the CTC regimen except that it
incorporated 2/3rd of the dose of each agent (Rodenhuis et al,
1996, 1999; Schrama et al, 2001). Patients received either one
(high-risk primary breast cancer) or two (refractory germ-cell
cancer) courses of CTC or two (metastatic ovarian cancer) or three
(metastatic breast or relapsing germ-cell cancer) courses of tCTC,
when possible every 4 weeks. Full details of the CTC and tCTC
regimens have been published previously (Rodenhuis et al, 1996,
1998, 1999, 2003; Schrama et al, 2001).
All protocols were approved by the Committee of Medical Ethics
of the Netherlands Cancer Institute and written informed consent
was obtained from all patients.
Sampling and analysis
During the 4-day CTC course, blood samples were collected from a
double lumen catheter inserted in a subclavian vein. Complete
pharmacokinetic profiles were assessed on two separate days,
always including day 1 and either day 3 or 4. Samples were taken at
30min after the start of CP infusion and at 60 (end of CP infusion),
90, 120 (end of carboplatin infusion), 150 (end of TT infusion),
165, 180, 210, 285, 390 and 660min. On day 5, an additional sample
was collected approximately 22h after the last CP infusion. A total
of approximately 21 samples were available per patient per course.
Sample pretreatment and bioanalysis of cyclophosphamide, 4-
hydroxycyclophosphamide, phosphoramide mustard, thiotepa,
tepa and carboplatin were conducted as described previously
(Van Warmerdam et al, 1995; Huitema et al, 1998, 2000a,b).
Pharmacokinetic analysis
Pharmacokinetic calculations for cyclophosphamide, 4-hydroxy-
cyclophosphamide and phosphoramide mustard were performed
based on two population pharmacokinetic models previously
developed in our institute (Huitema et al, 2001; De Jonge et al,
2004) using the nonlinear mixed effect modelling program
NONMEM (double precision, version V 1.1) (Beal and Sheiner,
1998). The applied model is schematically depicted in Figure 2.
Parameters were estimated using data of all patients included in
the present study. In brief, the model includes both the recognised
autoinduction process of cyclophosphamide resulting in increased
rate of 4-hydroxycyclophosphamide and phosphoramide mustard
formation in time, as well as the inhibitory effect of thiotepa on
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Figure 1 Metabolism of cyclophosphamide, with the bioactivation in the vertical direction and horizontally the inactivation processes.
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sthis induction. For more details on the model we refer to earlier
publications (Huitema et al, 2001; De Jonge et al, 2004).
Based on measured plasma concentrations in the individuals
included in this study and the population pharmacokinetic model
as presented in Figure 2, Bayesian estimates of the area under the
plasma concentration–time curves (AUCs) of 4-hydroxycyclo-
phosphamide and phosphoramide mustard were generated. These
estimates were obtained with the POSTHOC option of NONMEM
taking both the population pharmacokinetic parameters and the
individual data into account (Beal and Sheiner, 1998). AUCs of
thiotepa, tepa and carboplatin were calculated in a similar way
using previously developed population pharmacokinetic models
(Huitema et al, 2002; De Jonge et al, 2004).
Clinical diagnosis of VOD
The clinical diagnosis VOD was based on the occurrence of two of
the following events within 20 days of transplantation: hyperbilir-
ubinemia (total serum bilirubin 434.2mmoll
 1), hepatomegaly
(or right upper quadrant pain of liver origin) and ascites (Ayash
et al, 1990; McDonald et al, 1993). The occurrence of VOD was
registered in a dichotomous (e.g. no VOD or VOD) way.
Statistical analysis
Relationships between VOD, occurring after multiple courses, and
the cumulative AUCs of 4-hydroxycyclophosphamide and phos-
phoramide mustard were tested using logistic regression. Also
other possible determinants of VOD (exposure to thiotepa and its
metabolite tepa, carboplatin exposure or cisplatin pretreatment)
were tested in an univariate and subsequently multivariate way. In
order to assess whether the AUC of the first course is a prognostic
factor for toxicity after subsequent courses, logistic regression was
used with both the AUC of the first course and the number of
courses administered.
Significance of the logistic regression models was assessed with
the Wald statistic. The Statistical Service Solution for Windows
version 11.0 (SPSS Inc., Chicago, IL, USA) was used and a two-
sided significance level of 0.05 was used for all tests.
RESULTS
Data were available from a total number of 59 patients (115
courses). In Table 1, the details of the patient population and
treatment are summarised. In the first 32 patients (57 courses)
pharmacokinetic data were available for cyclophosphamide, 4-
hydroxycyclophosphamide, thiotepa, tepa and carboplatin, while
in the final 27 patients (58 courses) also data of phosphoramide
mustard were available.
A total of four patients experienced VOD. Three patients with
refractory germ-cell cancer developed VOD after a second CTC
course. One patient, treated for metastatic breast cancer developed
VOD after a second tCTC course. Of this latter patient, no
phosphoramide mustard data were available for both courses.
Figure 3A and B shows a comparison of the AUC of 4-
hydroxycyclophosphamide and phosphoramide mustard during
the first course between patients with and without VOD. A
significant relationship between the first course AUC of 4-
hydroxycyclophosphamide and the occurrence of VOD was found
(P¼0.003) while no significant relationship was found between the
first course phosphoramide mustard AUC and VOD (P¼0.101).
Mean AUC of 4-hydroxycyclophosphamide in the first course was
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Estimate  
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Figure 2 Population pharmacokinetic model of cyclophosphamide (CP)
and its metabolites 4-hydroxycyclophosphamide (4OHCP) and phosphor-
amide mustard (PM).
Table 1 Patients and treatment
Disease Regimen
Number of
patients
Number of
courses
Number of 1st
courses
Number of 2nd
courses
Number of 3rd
courses
High risk primary breast cancer 1 CTC 16 16 16
Metastatic breast cancer 3 tCTC 25 63 25 21 17
Refractory germ cell cancer 2 CTC 10 20 10 10
Refractory germ-cell cancer 3 tCTC 3 8 3 3 2
Metastatic ovarian cancer 2 tCTC 5 8 5 3
Total 59 115 59 37 19
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Figure 3 Area under the plasma concentration–time curves (AUCs) of
(A) 4-hydroxycyclophosphamide and (B) phosphoramide mustard of
patients with VOD (developed after subsequent courses) vs the remaining
population, with – being the mean of the data points.
Veno-occlusive disease and cyclophosphamide
ME de Jonge et al
1228
British Journal of Cancer (2006) 94(9), 1226–1230 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s134.5mMh in the patients without VOD and 184.5mMh
 1 in the
patients with VOD. For phosphoramide mustard, the mean first
course exposure was 526.7mMh
 1 in the patients without VOD and
792.0mMh
 1 in the patients with VOD. From these results it can be
concluded that the exposure to 4-hydroxycyclophosphamide is
predictive for hepatic damage after following courses.
No significant relationship was found between the total
cumulative 4-hydroxycyclophosphamide or phosphoramide mus-
tard AUC and the occurrence of VOD (P¼0.173 and 0.428,
respectively) in patients receiving two or more courses. Other
possible determinants of VOD (exposure to thiotepa and tepa,
carboplatin exposure or cisplatin pretreatment) did not result in
significant relationships.
DISCUSSION
The goal of this study was to assess the impact of exposure to
bioactivated cyclophosphamide on the occurrence of VOD caused
by the high-dose CTC chemotherapy regimen. We found that
increased exposures to 4-hydroxycyclophosphamide in course one
led to increased occurrence of VOD. Despite the low incidence of
VOD (four out of 59 patients developed VOD), statistically
significant conclusions could be drawn.
Hepatic injury resulting from treatment with high-dose cyclo-
phosphamide has been reported to be cyclophosphamide dose
related (Honjo et al, 1988) and may be caused by acrolein which is
a by-product in the bioactivation of cyclophosphamide (Figure 1).
Acrolein may cause liver dysfunction by binding to cytochrome
enzymes, hepatic macromolecules and nucleic acids (DeLeve,
1996). Inhibition of hepatic glutathione-S-transferase by acrolein
(Scott and Kirsch, 1988), as well as direct glutathione depletion
(DeLeve, 1996), may cause acrolein accumulation in the liver after
administration of high doses of cyclophosphamide. High-dose
busulphan may also cause a depletion of glutathione and
glutathione-S-transferase levels (Hassan et al, 2000). Therefore,
the combination cyclophosphamide/busulphan, regularly used in
the bone marrow transplantation setting, is often complicated by
hepatic toxicity (Nevill et al, 1991; McDonald et al, 1993).
Our results indicate that the exposure intensity to 4-hydro-
xycyclophosphamide during treatment may be important in the
development of VOD. Higher exposures to 4-hydroxycyclo-
phosphamide in the first course were indicative of the occurrence
of VOD later on, possibly because of liver damage not fully
recovered before administration of a next similar course (with
intrapatient AUC variation between courses of treatment being
23%). Total cumulative exposure to 4-hydroxycyclophosphamide
after multiple courses, however, was not significantly correlated,
although a trend was observed. This is exemplified by the fact that
patients treated with three courses of tCTC received in total the
same cyclophosphamide dose as patients receiving two courses of
CTC. However, VOD never occurred after 3rd courses of tCTC (in
total 19 patients) but occurred in three of the 10 patients receiving
two courses of full-dose CTC. Increased risk for VOD in the CTC
patients, compared with the tCTC patients, may therefore be
explained by administration of a similar total exposure in a shorter
time period. From these results it can be concluded that patients
receiving a higher exposure intensity to 4-hydroxycyclo-
phosphamide are more likely to develop hepatic damage.
In conclusion, a relationship between the occurrence of VOD
and pharmacokinetics of cyclophosphamide has been established.
This result indicates that the incidence of VOD may be reduced
with lower cyclophosphamide dose intensity or individualised
dosing of cyclophosphamide. Therapeutic drug monitoring may be
useful for adjusting a cyclophosphamide dose to target the 4-
hydroxycyclophosphamide exposure to a value consistent with low
toxicity.
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